摘要
目的研究人肝癌组织中是否存在生长激素受体(GHR)与胰岛素样生长因子Ⅱ受体(IGFⅡR)。方法采用免疫组织化学方法,对34例肝细胞性肝癌,26例癌旁组织,20例肝硬变组织及21例正常肝组织进行GHR、IGFⅡR的测定。结果GHR在肝癌标本中52.9%存在阳性表达,而在癌旁组织中阳性染色占88.5%,肝硬变组织占80.0%,正常肝组织占90.5%。在同样的肝癌标本中70.6%存在IGFⅡR阳性表达,在癌旁组织中阳性染色占76.9%,肝硬变组织占90.0%,正常肝组织占38.1%。结论肝癌患者中存在GHR的低度表达和IGFⅡR的高度表达,因此,临床上对肝癌病人使用生长激素治疗有可能促进肿瘤的生长。
Objective To investigate whether the growth hormone receptor （GHR） and insulin - like growth factor Ⅱ receptor （ IGF Ⅱ R） are present in human hepatocellular carcinoma （HCC）. Methods The GHR and IGF ⅡR were measured in samples of human HCC（34 cases）, the liver tissues adjacent to hepatocellular carcinoma （26 cases）, cirrhotic tissues （21 cases） , and control liver tissues （20 cases）by immunohistochemistry technique. Results The GHR and IGF Ⅱ R positive expression rate was 52.9% and 70, 6% in samples of hepatocellular carcinoma, 88.5% and 76.9% in adjacent tissue of HCC , 80.0% and 90. 0% in cirrhotic liver tissue, 90, 5% and 38.1% in normal liver tissue. Conclusion The lower expression of GHR and higher expression of IGF Ⅱ R are present in hepatocellular carcinoma. If we treat the patients of HCC with growth hormone, it can potentially accelerate the proliferation of tumor cells.
出处
《临床和实验医学杂志》
2007年第5期35-37,共3页
Journal of Clinical and Experimental Medicine
关键词
肝细胞癌
免疫组织化学
生长激素受体胰岛素样生长因子Ⅱ受体
Hepatocellular carcinoma
Immunohistochemistry
Growth hormone receptor
Insulin -like Growth Factor Ⅱ receptor
